Healthcare provider profile · identity verified

Elizabeth D Canete, MD

Family Practice · RANCHO CUCAMONGA, CA · NPI 1346357431

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	472	219
Lisinopril	Lisinopril	291	128
Amlodipine Besylate	Amlodipine Besylate	279	123
Losartan Potassium	Losartan Potassium	257	111
Rosuvastatin Calcium	Rosuvastatin Calcium	248	113
Levothyroxine Sodium	Levothyroxine Sodium	217	94
Meloxicam	Meloxicam	199	75
Metformin Hcl	Metformin Hcl	188	92
Hydrochlorothiazide	Hydrochlorothiazide	168	71
Gabapentin	Gabapentin	151	68
Simvastatin	Simvastatin	141	61
Glipizide	Glipizide	134	49
Potassium Chloride	Potassium Chloride	131	71
Atenolol	Atenolol	129	59
Omeprazole	Omeprazole	129	75
Ibuprofen	Ibuprofen	117	70
Metformin Hcl Er	Metformin Hcl	100	46
Albuterol Sulfate Hfa	Albuterol Sulfate	98	67
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	92	39
Pantoprazole Sodium	Pantoprazole Sodium	83	41
Furosemide	Furosemide	79	46
Alendronate Sodium	Alendronate Sodium	78	38
Pradaxa	Dabigatran Etexilate Mesylate	78	25
Triamcinolone Acetonide	Triamcinolone Acetonide	77	35
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	73	27
Trazodone Hcl	Trazodone Hcl	67	27
Humulin N Kwikpen	Insulin Nph Human Isophane	66	21
Metoprolol Tartrate	Metoprolol Tartrate	63	31
Tramadol Hcl	Tramadol Hcl	60	11
Azelastine Hcl	Azelastine Hcl	52	22
Bisoprolol Fumarate	Bisoprolol Fumarate	52	22
Lorazepam	Lorazepam	51	suppressed
Prednisone	Prednisone	51	45
Wixela Inhub	Fluticasone Propion/Salmeterol	50	23
Ozempic	Semaglutide	49	suppressed
Sertraline Hcl	Sertraline Hcl	46	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	43	12
Allopurinol	Allopurinol	42	22
Humulin N	Insulin Nph Human Isophane	41	13
Hydralazine Hcl	Hydralazine Hcl	41	16
Montelukast Sodium	Montelukast Sodium	40	14
Lovastatin	Lovastatin	39	15
Fluticasone Propionate	Fluticasone Propionate	36	17
Citalopram Hbr	Citalopram Hydrobromide	34	12
Fluoxetine Hcl	Fluoxetine Hcl	33	12
Tamsulosin Hcl	Tamsulosin Hcl	33	18
Clopidogrel	Clopidogrel Bisulfate	31	15
Famotidine	Famotidine	30	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	12
Cephalexin	Cephalexin	28	22
Valacyclovir	Valacyclovir Hcl	27	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	27	13
Benazepril Hcl	Benazepril Hcl	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	26	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Naproxen	Naproxen	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	suppressed
Terazosin Hcl	Terazosin Hcl	24	15
Fenofibrate	Fenofibrate	23	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	23	11
Alprazolam	Alprazolam	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Lidocaine	Lidocaine	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	19	19
Hydrocortisone	Hydrocortisone	19	suppressed
Ketoconazole	Ketoconazole	19	13
Nortriptyline Hcl	Nortriptyline Hcl	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Humulin R	Insulin Regular, Human	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	17	suppressed
Nystatin	Nystatin	17	11
Ondansetron Odt	Ondansetron	17	11
Spironolactone	Spironolactone	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Colchicine	Colchicine	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Arexvy	Rsvpref3 Antigen/As01e/Pf	15	15
Carvedilol	Carvedilol	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Finasteride	Finasteride	15	11
Levetiracetam	Levetiracetam	15	suppressed
Metoprolol Succinate	Metoprolol Succinate	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Alvesco	Ciclesonide	14	suppressed
Baclofen	Baclofen	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	14	12
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Eliquis	Apixaban	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Estradiol	Estradiol	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	12	suppressed
Jardiance	Empagliflozin	11	suppressed
Lactulose	Lactulose	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error